Early effects of paroxetine on serotonin storage, plasma levels, and urinary excretion: A randomized, double-blind, placebo-controlled trial

Journal of Clinical Psychopharmacology

Volumn 24, Issue 5, 2004, Pages 536-539

  Kotzailias, Nicole ^a   Marker, Michael ^a   Jilma, Bernd ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; PLACEBO; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTONIN BLOOD LEVEL; SEROTONIN RELEASE; SIDE EFFECT; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; URINARY EXCRETION; VASCULAR DISEASE; VASOCONSTRICTION;

ADULT; BLOOD PLATELETS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; MALE; METABOLIC CLEARANCE RATE; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 4644239381     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000138765.08235.46     Document Type: Article

References (27)

1. Wagstaff AJ, Cheer SM, Matheson AJ, et al. Spotlight on paroxetine in psychiatric disorders in adults. CNS Drugs. 2002;16(6):425-434.
2. Barbey JT, Roose SP. SSIU safety in overdose. J Clin Psychiatry. 1998;59(suppl 15):42-48.
3. Frasure-Smith N, Lesperance F. Depression and other psychological risks following myocardial infarction. Arch Gen Psychiatry. 2003;60(6): 627-636.
4. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6 month survival. JAMA. 1993;270:1819-1825.
5. Newman S. The psychological perspective: a professional view. Heart. 2003;89(suppl 2):ii16-ii18.
6. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003;108(1):32-36.
7. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001;104(16):1894-1898.
8. Serebruany VL, Glassman AH, Malinin AI, et al. For the Sertraline Antidepressant Heart Attack Randomized Trial Study Group. Platelet/ endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy [published erratum appears in Circulation. 108(25): 3165]. Circulation. E-pub 2003;108(8):939-944.
9. Serebruany VL, Glassman AH, Malinin AI, et al. For the Sertraline Antidepressant Heart Attack Randomized Trial Study Group. Platelet/ endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy [published erratum appears in Circulation. 108(25): 3165]. Circulation. E-pub 2003;108(8):939-944.
10. Barradas MA, Gill DS, Fonseca VA, et al. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Invest. 1988;18(4):399-404.
11. Golino P, Maseri A. Serotonin receptors in human coronary arteries. Circulation. 1994;90(3):1573-1575.
12. Golino P, Piscione F, Benedict CR, et al. Local effect of serotonin released during coronary angioplasty. N Engl J Med. 1994;330(8): 523-528.
13. Golino P, Piscione F, Willerson JT, et al. Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med. 1991;324(10): 641-648.
14. Satomura K, Takase B, Hamabe A, et al. Sarpogrelate, a specific 5HT2-receptor antagonist, improved coronary microcirculation in coronary artery disease. Clin Cardiol. 2002;25(1):28-32.
15. Pakala R, Willerson JT, Benedict CR. Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation. 1997;96(7):2280-2286.
16. De Clerck FF, Hermann AG. 5-Hydroxytryptamine and platelet aggregation. Fed Proc. 1983;42:228-232.
17. Dale GL, Friese P, Batar P, et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature. 2002;415(6868):175-179.
18. Alvarez JC, Gluck N, Arnulf I, et al. Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine. Clin Pharmacol Ther. 1999;66(6):617-624.
19. Hergovich N, Aigner M, Eichler HG, et al. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther. 2000;68(4):435-442.
20. Pratt LA, Ford DE, Crum RM, et al. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation. 1996;94(12):3123-3129.
21. van Zwieten PA. Pathophysiological relevance of serotonin. J Cardiovasc Pharmacol. 1987;10(suppl 3):19-25.
22. Winocour PH, Klimiuk P, Grennan A, et al. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest. 1988;18(4):399-404.
23. Tsuchiya H, Ohtani S, Takagi N, et al. High performance liquid Chromatographic analysis of time-dependent changes in urinary excretion of indoleamines following tryptophan administration. Biomed Chromatogr. 1989;3(4):157-160.
24. Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and pharmakokinetics of paroxetine in man. Acta Psychiatr Scand. 1989;80(suppl 350):60-75.
25. Sindrup SH, Brosen K, Gram LF, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther. 1992;51(3):278-287.
26. Racke K, Schworer H, Simson G. Effects of cigarette smoking or ingestion of nicotine on platelet 5-hydroxytryptamine (serotonin) levels in smokers and non-smokers. J Clin Invest. 1992;70(3-4):201-204.
27. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA. 1998;279(4):287-291.